Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 55, Issue 5, 1996, Pages 288-293

  Lems, W F ^a   Gerrits, M I ^a   Jacobs, J W G ^a   Van Vugt, R M ^a   Van Rijn, H J M ^a   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CORTICOSTEROID; DEXAMETHASONE; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029975310     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.5.288     Document Type: Article

References (38)

1. Lukert B P, Raisz L G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-64.
2. Adachi J D, Bensen W G, Hodsman A B. Corticosteroid-induced osteoporosis. Semin Arthritis Rlieum 1993; 22: 375-84.
3. Sambrook P N, Jones G. Corticosteroid osteoporosis. Br J Rheumatol 1995; 34: 8-12.
4. Adinoff A D, Hollister J R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-8.
5. Dyckman T R, Gluck O S, Murphy W A, Hahn T J, Hahn B H. Evaluation of factors associated with glucocorticoid-induced ostopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 28: 361-8.
6. Lems W F, Jahangier Z N, Jacobs J W G, Bijlsma J W J. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995; 13: 293-7.
7. Weusten B, Jacobs J W G, Bijlsma J W J. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 183-92.
8. Bijlsma J W J, Duursma S A, Huber-Bruning O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Arthritis Rheum Dis 1986; 45: 757-60.
9. Bijlsma J W J, Duursma S A, Bosch R, Raymakers J A, Huber-Brunin O. Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br J Rheumatol 1988; 27: 215-9.
10. Veen M J van der, Bijlsma J W J. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol 1992; 11: 402-5.
11. Risteli J, Melkko J, Niemi S, Risteli L. Use of a marker of collagen formation in osteoporosis studies. Calcif Tissue Int 1991; 49 (suppl): 24-5.
12. Ristdi J, Elomma I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40.
13. Eyre D. New markers of bone resorption. J Clin Endocrinol Metab 1992; 74:470-1.
14. Editorial. Pyridinium crosslinks as markers of bone resorption. Lancet 1992; 340: 278-9.
15. Colwell A, Russell R G G, Eastell R. Factors affecting the assay of urinary 3-hydroxy-pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993; 23: 341-9.
16. Arnett F C, Edworthy S M, Bloch D E, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas P D. Measurement of serum osteocalcin with a human specific two-site immunoradiometric assay. J Bone Miner Res 1992; 7: 1389-98.
18. Gerrits M I, Thijssen J H H, van Rijn H J M. Determination of the bone resorption markers pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin Chem 1995; 41: 571-4.
19. Seibel M J, Robins S P, Bilezikian J P. Urinary crosslinks of collagen. Trends Endocrinol Metab 1992; 3: 263-70.
20. Lems W F, Jacobs J W G, Brink H R van den, Rijn H J M van, Bijlsma J W J. Transient decrease in osteocalcin and markers of collagen type 1 formation during corticosteroid pulse therapy. Br J Rheumatol 1993; 32: 787-90.
21. Delmas P D. Biochemical markers of bone turnover. J Bone Miner Res 1993; 8: S549-55.
22. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994; 9: 1097-105.
23. Kollerup G, Hansen M, Horslev Petersen K. Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Br J Rheumatol 1994; 33: 816-20.
24. Eggelmeijer F, Papapoulos S E, Westedt M L, Paassen H C van, Dijkmans B A C, Breedveld F C. Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993; 32: 387-91.
25. Hall G M, Spector T D, Delmas P D. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1995; 7: 902-6.
26. Meunier P J, Dempster D W, Edouard C, Chapuy M C, Arlot M, Chardhon S. Bone histomorphometry in corticosteroid-induced osteoporosis in Cushing's syndrome. Adv Exp Med Biol 1984; 171: 191-200.
27. Thompson P W, Spector T D, James I T, Henderson E, Hart D J. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Br J Rheumatol 1992; 31: 759-61.
28. McDonald A G, McHenry P, Robins S P, Reid D M. Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. Br J Rheumatol 1994; 33: 16-9.
29. Astbury C, Bird H A, McLaren A M, Robins S P. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br J Rheumatol 1994; 33: 11-5.
30. Spector T D, James I T, Hall G M, Thompson P W, Perrett D, Hart D J. Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 1993; 12: 240-4.
31. Seibel M J, Gartenberg F, Silverberg S J, Ratcliffe A, Robins S P, Bilezikian J P. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Endocrinol Metab 1992; 74: 481-6.
32. Eastell R, Robins S P, Colwell T, Assiri A M A, Riggs B L, Russell R G G. Evaluation of bone turnover in type 1 osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 1993; 3: 255-60.
33. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas P D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641-9.
34. Risteli L, Risteli J, Moniz C. Measuring collagen degradation. Eur J Clin Invest 1993; 23: 339-40.
35. Delmas P D, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 1993; 8: 643-8.
36. Seyedin S M, Kung V T, Daniloff Y N, et al. Immunoassay for urinary pyridinoline: the new marker for bone resorption. J Bone Miner Res 1993; 8: 635-41.
37. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992; 66: 337-41.
38. Lems W F, Brink H R van den, Gerrits M I, Rijn H J M van, Bijlsma J W J. Effect of hormonal replacement therapy on osteocalcin and markers of collagen type 1 turnover in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis 1993; 52: 335-6.